In his weekly clinical update, Dr. Griffin discusses estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status, smart thermometer–based participatory surveillance to discern the role of children in household viral transmission during the COVID-19 pandemic, COVID-19 vaccine mandates, changing severity and epidemiology of adults hospitalized with COVID-19 in the United States after introduction of COVID-19 vaccines, effectiveness of COVID-19 treatment with Nirmatrelvir–Ritonavir or Molnupiravir among U.S. veterans, national trends in anticoagulation therapy for COVID-19 hospitalized adults in the United States, development of a definition of postacute sequelae of SARS-CoV-2 infection, neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms, long COVID clinical phenotypes up to six months after infection identified by latent class analysis of self-reported symptoms, and coronary microvascular health in symptomatic patients with prior COVID-19 infection.

In his weekly clinical update, Dr. Griffin discusses the potential for recurrent Mpox outbreaks among gay, bisexual, and other men who have sex with men, association between SARS-CoV-2 variants and frequency of acute symptoms, prospective study of key correlates for household transmission of SARS-CoV-2, Pfizer’s PAXLOVID™ receiving FDA approval for adult patients at high risk of progression to severe COVID-19, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, development of a definition of postacute sequelae of SARS-CoV-2 infection, COVID-19 and risk for mental disorders among adults in Denmark, risk of new post-COVID mental disorders higher only in older patients.

In his weekly clinical update, Dr. Griffin discusses the CDC HIV surveillance report, FDA voted in favor of approving the Abrysvo vaccine, canine olfactory detection of SARS-CoV-2-infected humans, safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years, and statement on the antigen composition of COVID-19 vaccines.

In his weekly clinical update, Dr. Griffin discusses variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC, ventilation in buildings, COVID-19 mortality among selective serotonin reuptake inhibitor users, risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses, trajectories of the evolution of post COVID-19 condition, and efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19.

In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19.

In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.

In his weekly clinical update, Dr. Griffin discusses completeness and spin of medRxiv preprints and associated published abstracts of COVID-19 randomized clinical trials, lessons learned from a COVID-19 dog screening pilot in California K-12 schools, SARS-CoV-2 reinfection and severity…

In his weekly clinical update, Dr. Griffin discusses an update on vaccine-derived poliovirus outbreaks, how the dream of wiping out polio might need a rethink, risk of death in patients hospitalized for COVID-19 vs seasonal Influenza in fall-winter, French Mpox cluster includes fully vaccinated patients, two individuals with potential Mpox virus reinfection, epidemiologic and clinical features of Mpox-associated deaths, FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines, SARS-CoV-2 during Omicron variant predominance among infants born to people with SARS-CoV-2, severe maternal morbidity and mortality of pregnant patients with COVID-19 infection during the early pandemic period in the US, sickness presenteeism in healthcare workers during the COVID-19 pandemic, ventilation improvements among k–12 public school districts, risk factors and vectors for SARS-CoV-2 household transmission, SARS-CoV-2 neutralizing antibodies after bivalent versus monovalent, durability of bivalent boosters against Omicron subvariants, Nirmatrelvir and risk of hospital admission or death in adults with COVID-19, evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19, effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19, efficacy and safety of Anakinra plus standard of care for patients with severe COVID-19, higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support, risk of autoimmune diseases in patients with COVID-19, definition of post–COVID-19 condition among published research studies, and sleep disturbance severity and correlates in post-acute sequelae of COVID-19. 

In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.

In his weekly clinical update, Dr. Griffin discusses how antibiotics don’t reduce risk of death from viral respiratory infections, norovirus infections continue to rise in the US, ABO blood types and SARS-CoV-2 infection assessed using seroprevalence data in a large population-based sample, maternal third dose of BNT162b2 mRNA vaccine and risk of infant COVID-19 hospitalization, association of treatment with Nirmatrelvir and the risk of Post–COVID-19 condition, mechanically ventilated patients with COVID-19 had a higher chance of in-hospital death if treated with high-flow nasal cannula oxygen before intubation, high-flow nasal cannula and outcomes in COVID-19, severe infection and risk of Cardiovascular disease, and the risk factors associated with post−COVID-19 condition.